Intervention of Nicotinamide Mononucleotide in Middle-aged and Elderly People (NCT06592859) | Clinical Trial Compass
RecruitingNot Applicable
Intervention of Nicotinamide Mononucleotide in Middle-aged and Elderly People
China240 participantsStarted 2023-08-23
Plain-language summary
This study is a single-center, randomized, double-blind, placebo-controlled clinical trial investigating a pharmacological intervention for aging. Its primary objective is to evaluate the efficacy of NMN while ensuring the safety of oral administration, with the aim of identifying effective strategies to delay aging and improve the quality of life in the elderly population. The main outcomes of this study are to characterize the patterns of NMN efficacy across different populations and to identify sensitive biomarkers that reflect responsiveness to the intervention.
Who can participate
Age range39 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Local residents of Quzhou or living in Quzhou for over ten years.
✓. age 40-50 and 60-70 years old, no major bad habits.
✓. Gender unlimited.
✓. in good health and has not undergone major surgery within half a year.
✓. Be able to communicate well with researchers and cooperate with the work during the study.
✓. Written informed consent can be signed voluntarily.
Exclusion criteria
✕. Alcoholism, heavy smoking (more than 5 packs/day, 20 cigarettes per pack), drug abuse or substance abuse.
✕. Participants are conducting other clinical trials or using any research drugs or equipment for treatment within 30 days before enrollment (including but not limited to aspirin, metformin, resveratrol, vitamin C, etc.).
✕. Obesity (bmi more than 30).
✕
What they're measuring
1
Comprehensive evaluation of NMN in reducing biological age